Please complete the information below to generate an interpretation report. We will not save this information, so please download and save the PDF report once generated.
To view examples of what an interpretation of a HeartFlow Analysis can look like, please download our Interpretations guide provided by Dr. Jonathon Leipsic.
View three case examples interpreted by:
Dr. Jonathon Leipsic, FRCPC, FSCCT
Past President of SCCT
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patientโs clinical history, symptoms, and other diagnostic tests, as well as the clinicianโs professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
ยฉ 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
ใชใณใฉใคใณๆๅบใใฉใผใ ใใ็ ็ฉถๅฉๆ้ใ็ณ่ซใใฆใใ ใใใ
HeartFlow FFRCT ๅๆใฏใๆ่ณๆ ผใฎ่จๅบๅปใซใใ่จๅบ็ใซๅฎๅฎใใ็็ถใฎใใๅ ็ถๅ่็พๆฃๆฃ่ ใธใฎไฝฟ็จใ็ฎ็ใจใใๅๅฅๅใใใๅฟ่ๆคๆปใงใใ HeartFlow Analysis ใซใใฃใฆๆไพใใใๆ ๅ ฑใฏใ่ณๆ ผใฎใใ่จๅบๅปใๆฃ่ ใฎ็ ๆญดใ็็ถใใใฎไปใฎ่จบๆญๆคๆปใใใใณ่จๅบๅปใฎๅฐ้็ๅคๆญใจ็ตใฟๅใใใฆไฝฟ็จโโใใใใจใ็ฎ็ใจใใฆใใพใใ
ใใใซ่ณชๅใใใๅ ดๅใฏใใใฎใกใใปใผใธใ้ใใฆใใฉใผใ ใซ่จๅ ฅใใใใใตใใผใ ใใผใ ใซใ้ป่ฉฑใใ ใใใ: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Womenโs Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.